Monast (Montelukast)

Montelukast blocks the CysLT1 receptor, a binding site for cysteinyl leukotrienes such as leukotriene D4. By preventing these mediators from activating the receptor, it reduces bronchoconstriction, mucus production, and inflammatory cell recruitment in the airways, leading to better breathing and fewer allergy symptoms.

The specific dose of Monast is determined by the prescribing clinician based on the patient’s age, weight, condition severity and other medical factors. Healthcare providers follow approved dosing guidelines and adjust as needed for optimal therapeutic effect.

Montelukast is classified as Pregnancy Category B, indicating no evidence of risk in animal studies and limited human data. It may be used during pregnancy if the potential benefit justifies any risk. While it passes into breast milk in small amounts, breastfeeding is generally considered acceptable with clinical monitoring.

To request Monast, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Monast (montelukast) belongs to the leukotriene receptor antagonist class, offering an oral alternative to inhaled corticosteroids or long‑acting beta‑agonists. It is especially useful for patients who prefer a once‑daily tablet, have difficulty using inhalers, or need additional control of allergic rhinitis alongside asthma.

Monast should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original container, protect them from moisture and direct sunlight, and ensure they are out of reach of children.

Monast is taken orally, usually once daily in the evening, with or without food. The tablet should be swallowed whole with a glass of water and not chewed or crushed, unless otherwise directed by a healthcare professional.

Serious but rare risks include angioedema, severe skin reactions such as Stevens‑Johnson syndrome, hepatic injury, and neuropsychiatric events like mood changes or suicidal thoughts. Patients should seek immediate medical attention if they experience swelling of the face or throat, rash, jaundice, or significant changes in mood.

Monast is contraindicated in individuals with a known hypersensitivity to montelukast or any of its excipients. Caution is advised for patients with severe liver disease, and it should be avoided in those taking strong enzyme‑inducing drugs that may markedly reduce its effectiveness.